Smallpox vaccine provides cross-protection against all orthopoxviruses and can be used to protect individuals at risk against these viruses.Since May 2022, cases of monkeypox have been reported and transmission has occurred in a number of countries where it was not previously reported, including Canada.The monkeypox virus is an orthopoxvirus that is genetically related to the variola virus.Remaining variola virus (causative agent of smallpox) stocks are kept in two World Health Organization ( WHO) reference laboratories.Naturally occurring smallpox disease was eradicated by 1977 through a worldwide vaccination program.Smallpox is a systemic viral illness with a characteristic rash that can have a 15% to 45% or higher mortality rate in an unimmunized population.First and second generation smallpox vaccines and immunoglobulin safety and adverse events.Simultaneous administration with other vaccines.Vaccine and immunoglobulin administration.Efficacy, effectiveness and immunogenicity.
Preparations authorized for use in Canada.Last complete chapter revision: January 2014 On this page June 10, 2022: NACI Rapid Response: Interim guidance on the use of Imvamune ® in the context of monkeypox outbreaks in Canada.September 23, 2022: NACI Rapid Response: Updated interim guidance on Imvamune ® in the context of ongoing monkeypox outbreaks.September 27, 2022: Quick reference guide on use of Imvamune ® for health care professionals in the context of monkeypox outbreaks in Canada.For this information, refer to the following: December 2022 - This chapter was updated to reflect guidance based on current evidence and the National Advisory Committee on Immunization's ( NACI's) expert opinion on the use of Imvamune ® in the context of monkeypox outbreaks in Canada.Last partial content update (see Table of Updates): December 2022 We'll be updating our content to reflect this change. On November 28, 2022, the World Health Organization began using 'mpox' as the preferred term for monkeypox disease.
0 kommentar(er)
